{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-008940","form_type":"8-K","ticker":"RCKT","cik":"0001281895","company_name":"ROCKET PHARMACEUTICALS, INC.","filed_at":"2023-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.212442+00:00","generated_at":"2026-06-18T23:15:01.528892+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Rocket Pharma reports Q4 2022 net loss of $66.7M; cash $399.7M; pipeline on track for 2023 regulatory filings","bullets":["Net loss $66.7M ($0.92/sh) in Q4 2022 vs $44.2M ($0.69) in Q4 2021; full-year net loss $221.9M ($3.26) vs $169.1M ($2.67).","Cash, cash equivalents and investments $399.7M as of Dec 31, 2022; expected runway through 2024.","Plans BLA submissions: LAD-I in Q2 2023, Fanconi Anemia in Q4 2023; Phase 2 pivotal for Danon Disease (RP-A501) starts Q2 2023.","FDA granted RMAT designation for RP-A501 (Danon Disease); acquired Renovacor in Dec 2022 adding BAG3-DCM program.","Raised $197.7M in 2022 via follow-on, ATM, and Renovacor cash; appointed new board member and executives."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-008940","json":"https://secwatch.observer/filing/0001140361-23-008940.json","markdown":"https://secwatch.observer/filing/0001140361-23-008940.md","text":"https://secwatch.observer/filing/0001140361-23-008940.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1281895/000114036123008940/0001140361-23-008940-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1281895/000114036123008940/brhc10048939_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T23:15:01.528892+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"815de7e52f0107743291eebf55b423e246b90437","claim":"ROCKET PHARMACEUTICALS, INC. reported financial results for the quarter and year ended December 31, 2022.","evidence_excerpt":"On February 27, 2023, Rocket Pharmaceuticals, Inc. announced its financial results for the quarter and year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1281895/000114036123008940/0001140361-23-008940-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter and year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}